BioCryst Pharmaceuticals, Inc. (BCRX) Can’t Be Less Risky. The Stock Formed a Bullish Descending Triangle

December 8, 2017 - By Winifred Garcia

Investors sentiment increased to 1.68 in Q2 2017. Its up 0.18, from 1.5 in 2017Q1. It increased, as 15 investors sold BioCryst Pharmaceuticals, Inc. shares while 19 reduced holdings. 18 funds opened positions while 39 raised stakes. 66.24 million shares or 8.58% more from 61.01 million shares in 2017Q1 were reported.
Principal Fin Grp reported 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Tiaa Cref Invest Management Limited Com owns 468,882 shares for 0% of their portfolio. Proshare Advsr Limited Co has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 48,354 shares. Jennison Assocs Llc accumulated 0.01% or 2.08 million shares. 11.72 million were accumulated by Baker Bros Advsrs Limited Partnership. Sg Americas Securities Llc holds 0% or 13,588 shares. Eventide Asset Mgmt Llc accumulated 290,000 shares. Envestnet Asset Mngmt stated it has 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Schwab Charles Management Inc reported 307,811 shares or 0% of all its holdings. Glenmede Tru Na, a Pennsylvania-based fund reported 200 shares. California Employees Retirement reported 0% stake. 69,320 are held by Federated Invsts Pa. Dafna Management Ltd Co owns 591,128 shares. 317,899 are owned by Morgan Stanley. Jpmorgan Chase And Com has invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).

The stock of BioCryst Pharmaceuticals, Inc. (BCRX) formed a descending triangle with $4.75 target or 4.00 % above today’s $4.57 share price. The 7 months triangle pattern indicates low risk for the $449.71M company. If the $4.75 price target is reached, the company will be worth $17.99M more.
The descending triangle is in our view more reliable than the ascending one. The descending triangle pattern has break even failure rate for up and down breakouts of 7% and 16%, respectively. The average rise and decline is 47% and 16%. The throwback or so called pullback rates are: 37% and 54%. The stocks meeting their targets is high for this type of breakout: 84% and 54% percent.

The stock decreased 0.44% or $0.02 during the last trading session, reaching $4.57. About 663,349 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since December 8, 2016 and is uptrending. It has outperformed by 58.38% the S&P500.

Analysts await BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report earnings on February, 26. They expect $-0.15 EPS, down 150.00 % or $0.09 from last year’s $-0.06 per share. After $-0.18 actual EPS reported by BioCryst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -16.67 % EPS growth.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage

Among 13 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. BioCryst Pharmaceuticals had 31 analyst reports since August 7, 2015 according to SRatingsIntel. JMP Securities upgraded the stock to “Market Outperform” rating in Friday, December 16 report. As per Thursday, November 2, the company rating was maintained by RBC Capital Markets. The firm has “Neutral” rating by JP Morgan given on Tuesday, February 9. Needham downgraded the stock to “Hold” rating in Tuesday, February 9 report. H.C. Wainwright maintained it with “Buy” rating and $10.0 target in Wednesday, November 8 report. The rating was maintained by Jefferies on Friday, August 5 with “Hold”. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Buy” rating by H.C. Wainwright on Tuesday, August 8. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has “Overweight” rating given on Wednesday, September 6 by JP Morgan. The stock has “Underperform” rating by Bank of America on Wednesday, November 11. The firm has “Buy” rating by Jefferies given on Wednesday, January 6.

More news for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) were recently published by: Seekingalpha.com, which released: “BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q3 2017 Results …” on November 07, 2017. Prnewswire.com‘s article titled: “Biotech Stock Performance Review — BioCryst Pharma, Celgene, Exelixis, and Geron” and published on November 21, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: